The report is an in-depth, 85 page analysis of Heliospectra, including its technology, market opportunity, business model, growth strategy, risks, management team, overall positioning in the market as well as a financial estimates.
The Redeye report states, “With an updated product portfolio and strengthened organization, Heliospectra is well positioned to rapidly grow sales in the booming medical plant segment and the greenhouse cultivation segment…. We believe Heliospectra’s efforts will pay off and expect sales of SEK 55 million in 2016 and continued strong growth going forward. For 2018, we expect sales to reach 120 million and EBIT to be positive for the first time in the company’s history.”
Mr. Staffan Hillberg, Heliospectra’s CEO, commented, “Our advanced lighting system, patented biofeedback system and superior lamp engineering helps growers in different agricultural sectors grow products efficiently and cost-effectively, in order to help solve the global food security and scarcity challenges. With a world-class management team and the new product additions made during the end of 2015 we are certain that we are looking towards an exciting 2016.”
The full company analysis is available for download here: